Sentences with phrase «with immune checkpoint blockade»

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

«Cancers evade immunotherapy by «discarding the evidence» of tumor - specific mutations: Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs.»

Researchers found the gene therapy approach had stronger results when used in combination with either depletion of immunosuppressive cells from the tumor mass or with immune checkpoint blockade.

Their study of fecal samples from 105 patients treated with immune checkpoint blockade indicates that certain characteristics of patients» microbiomes correlate with slower disease progression while other qualities are associated with rapid worsening of the disease.

Not exact matches

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

One phase I trial of an immune checkpoint blockade drug combined with two established targeted therapies yielded 40 - 50 percent response rates among patients with metastatic kidney cancer.

Obesity is associated with increased inflammation, which could improve the effectiveness of checkpoint blockade drugs that unleash an immune response against cancer.

Checkpoint blockade therapy works by interfering with cancer's ability to turn off the body's immune reaction.

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

A Brief Report published recently in the New England Journal of Medicine detailed two cases of patients treated with combination immune checkpoint blockade for metastatic melanoma who developed myositis, early progressive and refractory cardiac electrical instability, and myocarditis.

The blockade of immune checkpoints with antibodies (Ab) anti-CTLA-4, anti-PD1 and anti-PD-L1, has given impressive clinical results and manageable safety profiles.

In melanoma, an increase in overall mutational and neoantigen load — novel tumor - specific antigens that can be recognized by the immune system — was associated with clinical benefit from checkpoint blockade.

It is also the first in an emerging class of therapies called «checkpoint blockade,» which enhance the immune system's ability to attack cancer by interfering with immunological checkpoints that slow or stop immune cell activation and proliferation in the presence of tumors or chronic viral infection.

Along with checkpoint blockade antibodies, vaccines, and other immunotherapies, BiTEs are helping to turn our immune system into a powerful defense against this disease.